{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:19:04Z","timestamp":1771017544116,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/eurheartj\/ehi231","type":"journal-article","created":{"date-parts":[[2005,3,22]],"date-time":"2005-03-22T01:13:03Z","timestamp":1111453983000},"page":"897-905","source":"Crossref","is-referenced-by-count":130,"title":["Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia"],"prefix":"10.1093","volume":"26","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mason W.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Macdonell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Perevozskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yale B.","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Gumbiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"key\n\t\t\t\t20180328152803_EHI231C1","doi-asserted-by":"crossref","unstructured":"Durrington P. Dyslipidaemia. Lancet2003;362:717\u2013731.","DOI":"10.1016\/S0140-6736(03)14234-1"},{"key":"key\n\t\t\t\t20180328152803_EHI231C2","doi-asserted-by":"crossref","unstructured":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA2001;285:2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"key\n\t\t\t\t20180328152803_EHI231C3","doi-asserted-by":"crossref","unstructured":"Fazio S, Linton MF. The role of fibrates in managing hyperlipidaemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep2004;6:148\u2013157.","DOI":"10.1007\/s11883-004-0104-8"},{"key":"key\n\t\t\t\t20180328152803_EHI231C4","unstructured":"Product Information. TRICOR (fenofibrate tablets). February, 2003. North Chicago, IL, Abbott Laboratories."},{"key":"key\n\t\t\t\t20180328152803_EHI231C5","doi-asserted-by":"crossref","unstructured":"Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin2002;18:269\u2013276.","DOI":"10.1185\/030079902125000516"},{"key":"key\n\t\t\t\t20180328152803_EHI231C6","doi-asserted-by":"crossref","unstructured":"Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination: therapy for hyperlipidaemia: a review. Curr Med Res Opin2003;19:155\u2013168.","DOI":"10.1185\/030079903125001668"},{"key":"key\n\t\t\t\t20180328152803_EHI231C7","doi-asserted-by":"crossref","unstructured":"Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs2003;3:169\u2013178.","DOI":"10.2165\/00129784-200303030-00003"},{"key":"key\n\t\t\t\t20180328152803_EHI231C8","doi-asserted-by":"crossref","unstructured":"Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother2001;35:908\u2013917.","DOI":"10.1345\/aph.10315"},{"key":"key\n\t\t\t\t20180328152803_EHI231C9","unstructured":"van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther1997;283:157\u2013163."},{"key":"key\n\t\t\t\t20180328152803_EHI231C10","doi-asserted-by":"crossref","unstructured":"Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J2003;24:729\u2013741.","DOI":"10.1016\/S0195-668X(02)00807-2"},{"key":"key\n\t\t\t\t20180328152803_EHI231C11","doi-asserted-by":"crossref","unstructured":"Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol2002;90:1092\u20131097.","DOI":"10.1016\/S0002-9149(02)02798-4"},{"key":"key\n\t\t\t\t20180328152803_EHI231C12","doi-asserted-by":"crossref","unstructured":"Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, LeBeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther2001;23:1209\u20131230.","DOI":"10.1016\/S0149-2918(01)80102-8"},{"key":"key\n\t\t\t\t20180328152803_EHI231C13","unstructured":"Zhu Y, Statkevich P, Kosoglou T, Zambas D, Patrick J, Cayen MN, Batra V. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. (Abstract). Clinical Pharmacol Ther2000;62:152."},{"key":"key\n\t\t\t\t20180328152803_EHI231C14","doi-asserted-by":"crossref","unstructured":"Kosoglou T, Statkevich P, Fruchart JC, Pember LJC, Reyderman L, Cutler DL, Guillaume M, Maxwell SE, Veltri EP. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin2004;20:1197\u20131207.","DOI":"10.1185\/030079903125004277"},{"key":"key\n\t\t\t\t20180328152803_EHI231C15","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104:3046\u20133051.","DOI":"10.1161\/hc5001.100624"},{"key":"key\n\t\t\t\t20180328152803_EHI231C16","doi-asserted-by":"crossref","unstructured":"Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation2003;107:1733\u20131737.","DOI":"10.1161\/01.CIR.0000057982.50167.6E"},{"key":"key\n\t\t\t\t20180328152803_EHI231C17","doi-asserted-by":"crossref","unstructured":"Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol1998;81:26B\u201331B.","DOI":"10.1016\/S0002-9149(98)00034-4"},{"key":"key\n\t\t\t\t20180328152803_EHI231C18","doi-asserted-by":"crossref","unstructured":"Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin+fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol2003;92:794\u2013797.","DOI":"10.1016\/S0002-9149(03)00885-3"},{"key":"key\n\t\t\t\t20180328152803_EHI231C19","doi-asserted-by":"crossref","unstructured":"Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidaemia (The SAFARI Trial). Am J Cardiol2005;95:462\u2013468.","DOI":"10.1016\/j.amjcard.2004.10.012"},{"key":"key\n\t\t\t\t20180328152803_EHI231C20","doi-asserted-by":"crossref","unstructured":"Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidaemia. Diabetes Care2002;25:1198\u20131202.","DOI":"10.2337\/diacare.25.7.1198"},{"key":"key\n\t\t\t\t20180328152803_EHI231C21","doi-asserted-by":"crossref","unstructured":"Kiortsis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidaemia. Eur J Clin Pharmacol2000;56:631\u2013635.","DOI":"10.1007\/s002280000213"},{"key":"key\n\t\t\t\t20180328152803_EHI231C22","doi-asserted-by":"crossref","unstructured":"Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200\u2005mg\/day) to simvastatin (10\u2005mg\/day) in patients with combined hyperlipidaemia and metabolic syndrome. Am J Cardiol2003;91:956\u2013960.","DOI":"10.1016\/S0002-9149(03)00111-5"},{"key":"key\n\t\t\t\t20180328152803_EHI231C23","doi-asserted-by":"crossref","unstructured":"Liamis G, Kakafika A, Bairaktari E, Miltiadous G, Tsimihodimos V, Goudevenos J, Achimastos A, Elisaf M. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidaemia. Curr Med Res Opin2002;18:125\u2013128.","DOI":"10.1185\/030079902125000372"},{"key":"key\n\t\t\t\t20180328152803_EHI231C24","doi-asserted-by":"crossref","unstructured":"Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis1996;7:843\u2013850.","DOI":"10.1097\/00019501-199611000-00009"},{"key":"key\n\t\t\t\t20180328152803_EHI231C25","doi-asserted-by":"crossref","unstructured":"Vakkilainen J, Steiner G, Ansquer JC, Perttunen-Nio H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care2002;25:627\u2013628.","DOI":"10.2337\/diacare.25.3.627"},{"key":"key\n\t\t\t\t20180328152803_EHI231C26","doi-asserted-by":"crossref","unstructured":"Armstrong SC, Cozza KL, Sandson NB. Six patterns of drug-drug interactions. Psychosomatics2003;44:255\u2013258.","DOI":"10.1176\/appi.psy.44.3.255"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/26\/9\/897\/9355086\/ehi231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T11:55:43Z","timestamp":1586174143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/26\/9\/897\/2888082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,21]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,3,21]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi231","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5]]},"published":{"date-parts":[[2005,3,21]]}}}